Claritas Pharmaceuticals, Inc. CLAZF
OTC PK
| 09/30/2021 | 06/30/2021 | 03/31/2021 | |||
|---|---|---|---|---|---|
| Net Income | 143.83% | 77.57% | -116.50% | ||
| Total Depreciation and Amortization | -- | -- | -- | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | -78.77% | -86.88% | 118.63% | ||
| Change in Net Operating Assets | 4.65% | 4,052.17% | -2,353.57% | ||
| Cash from Operations | -205.24% | 306.06% | -1,146.15% | ||
| Capital Expenditure | -- | -- | -- | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -- | -- | -- | ||
| Cash from Investing | -- | -- | -- | ||
| Total Debt Issued | -- | 73.53% | -- | ||
| Total Debt Repaid | -- | -- | -- | ||
| Issuance of Common Stock | -99.53% | -- | -- | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -- | -- | -- | ||
| Cash from Financing | -99.53% | 73.53% | -- | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | -158.46% | 3,075.00% | 179.31% | ||